MRNA-Based Genetic Reprogramming

Overview

Journal Mol Ther

Publisher Cell Press

Specialties Molecular Biology
Pharmacology

Date 2019 Jan 2

PMID 30598301

Citations 44

Authors

Luigi Warren

Cory Lin

Affiliations

Soon will be listed here.

Abstract

The discovery that ordinary skin cells can be turned into pluripotent stem cells by the forced expression of defined factors has raised hopes that personalized regenerative treatments based on immunologically compatible material derived from a patient's own cells might be realized in the not-too-distant future. A major barrier to the clinical use of induced pluripotent stem cells (iPSCs) was initially presented by the need to employ integrating viral vectors to express the factors that induce an embryonic gene expression profile, which entails potentially oncogenic alteration of the normal genome. Several "non-integrating" reprogramming systems have been developed over the last decade to address this problem. Among these techniques, mRNA reprogramming is the most unambiguously "footprint-free," most productive, and perhaps the best suited to clinical production of stem cells. Herein, we discuss the origins of the mRNA-based reprogramming system, its benefits and drawbacks, recent technical improvements that simplify its application, and the status of current efforts to industrialize this approach to mass-produce human stem cells for the clinic.

Citing Articles

UTR-Insight: integrating deep learning for efficient 5' UTR discovery and design.

Pan S, Wang H, Zhang H, Tang Z, Xu L, Yan Z BMC Genomics. 2025; 26(1):107.

PMID: 39905334 PMC: 11796101. DOI: 10.1186/s12864-025-11269-7.

Engineered biomaterials in stem cell-based regenerative medicine.

Zhu F, Nie G, Liu C Life Med. 2025; 2(4):lnad027.

PMID: 39872549 PMC: 11749850. DOI: 10.1093/lifemedi/lnad027.

Combining the induced pluripotent stem cell (iPSC) technology with chimeric antigen receptor (CAR)-based immunotherapy: recent advances, challenges, and future prospects.

Alidadi M, Barzgar H, Zaman M, Paevskaya O, Metanat Y, Khodabandehloo E Front Cell Dev Biol. 2024; 12:1491282.

PMID: 39624236 PMC: 11609223. DOI: 10.3389/fcell.2024.1491282.

The Role of Human-Induced Pluripotent Stem Cells in Studying Cardiac Channelopathies.

Begovic M, Schneider L, Zhou X, Hamdani N, Akin I, El-Battrawy I Int J Mol Sci. 2024; 25(22).

PMID: 39596103 PMC: 11593457. DOI: 10.3390/ijms252212034.

Bridging the gap: a translational perspective in spinal cord injury.

Hassan O, Takamiya S, Asgarihafshejani A, Fehlings M Exp Biol Med (Maywood). 2024; 249:10266.

PMID: 39391076 PMC: 11464315. DOI: 10.3389/ebm.2024.10266.

References

El-Sayed A, Zhang Z, Zhang L, Liu Z, Abbott L, Zhang Y . Pluripotent state induction in mouse embryonic fibroblast using mRNAs of reprogramming factors. Int J Mol Sci. 2014; 15(12):21840-64. PMC: 4284681. DOI: 10.3390/ijms151221840. View

Van Tendeloo V, Ponsaerts P, Lardon F, Nijs G, Lenjou M, Van Broeckhoven C . Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. Blood. 2001; 98(1):49-56. DOI: 10.1182/blood.v98.1.49. View

Yu J, Hu K, Smuga-Otto K, Tian S, Stewart R, Slukvin I . Human induced pluripotent stem cells free of vector and transgene sequences. Science. 2009; 324(5928):797-801. PMC: 2758053. DOI: 10.1126/science.1172482. View

Yoshida Y, Takahashi K, Okita K, Ichisaka T, Yamanaka S . Hypoxia enhances the generation of induced pluripotent stem cells. Cell Stem Cell. 2009; 5(3):237-41. DOI: 10.1016/j.stem.2009.08.001. View

Steichen C, Luce E, Maluenda J, Tosca L, Moreno-Gimeno I, Desterke C . Messenger RNA- versus retrovirus-based induced pluripotent stem cell reprogramming strategies: analysis of genomic integrity. Stem Cells Transl Med. 2014; 3(6):686-91. PMC: 4039453. DOI: 10.5966/sctm.2013-0158. View

Warren L, Manos P, Ahfeldt T, Loh Y, Li H, Lau F . Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell. 2010; 7(5):618-30. PMC: 3656821. DOI: 10.1016/j.stem.2010.08.012. View

Angel M, Yanik M . Innate immune suppression enables frequent transfection with RNA encoding reprogramming proteins. PLoS One. 2010; 5(7):e11756. PMC: 2909252. DOI: 10.1371/journal.pone.0011756. View

Brady J, Li M, Suthram S, Jiang H, Wong W, Blau H . Early role for IL-6 signalling during generation of induced pluripotent stem cells revealed by heterokaryon RNA-Seq. Nat Cell Biol. 2013; 15(10):1244-52. PMC: 4100556. DOI: 10.1038/ncb2835. View

Rabinovich P, Komarovskaya M, Wrzesinski S, Alderman J, Budak-Alpdogan T, Karpikov A . Chimeric receptor mRNA transfection as a tool to generate antineoplastic lymphocytes. Hum Gene Ther. 2008; 20(1):51-61. PMC: 2855249. DOI: 10.1089/hum.2008.068. View

10.

Paull D, Sevilla A, Zhou H, Hahn A, Kim H, Napolitano C . Automated, high-throughput derivation, characterization and differentiation of induced pluripotent stem cells. Nat Methods. 2015; 12(9):885-92. DOI: 10.1038/nmeth.3507. View

11.

Kariko K, Buckstein M, Ni H, Weissman D . Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA. Immunity. 2005; 23(2):165-75. DOI: 10.1016/j.immuni.2005.06.008. View

12.

Durruthy-Durruthy J, Briggs S, Awe J, Ramathal C, Karumbayaram S, Lee P . Rapid and efficient conversion of integration-free human induced pluripotent stem cells to GMP-grade culture conditions. PLoS One. 2014; 9(4):e94231. PMC: 3981795. DOI: 10.1371/journal.pone.0094231. View

13.

Kariko K, Muramatsu H, Welsh F, Ludwig J, Kato H, Akira S . Incorporation of pseudouridine into mRNA yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 2008; 16(11):1833-40. PMC: 2775451. DOI: 10.1038/mt.2008.200. View

14.

Kawai T, Akira S . Antiviral signaling through pattern recognition receptors. J Biochem. 2006; 141(2):137-45. DOI: 10.1093/jb/mvm032. View

15.

Dolgin E . Business: The billion-dollar biotech. Nature. 2015; 522(7554):26-8. DOI: 10.1038/522026a. View

16.

Takahashi K, Yamanaka S . Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006; 126(4):663-76. DOI: 10.1016/j.cell.2006.07.024. View

17.

Poleganov M, Eminli S, Beissert T, Herz S, Moon J, Goldmann J . Efficient Reprogramming of Human Fibroblasts and Blood-Derived Endothelial Progenitor Cells Using Nonmodified RNA for Reprogramming and Immune Evasion. Hum Gene Ther. 2015; 26(11):751-66. DOI: 10.1089/hum.2015.045. View

18.

Graf T, Enver T . Forcing cells to change lineages. Nature. 2009; 462(7273):587-94. DOI: 10.1038/nature08533. View

19.

Ni Y, Zhao Y, Warren L, Higginbotham J, Wang J . cGMP Generation of Human Induced Pluripotent Stem Cells with Messenger RNA. Curr Protoc Stem Cell Biol. 2019; 39(1):4A.6.1-4A.6.25. DOI: 10.1002/cpsc.18. View

20.

Bhutani K, Nazor K, Williams R, Tran H, Dai H, Dzakula Z . Whole-genome mutational burden analysis of three pluripotency induction methods. Nat Commun. 2016; 7:10536. PMC: 4762882. DOI: 10.1038/ncomms10536. View